AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02753595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biologic: PEGylated recombinant human hyaluronidase
Description: PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
Study NCT04037475 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: photodynamic therapy herpes labialis
Description: Patients will receive Photodynamic Therapy (PDT), irradiations will be performed with the Laser Duo® red laser diode (MMOptics, São Carlos, SP, Brazil) with a wavelength of 660 nm, with a power of 100 mW, the energy density of 300 J / cm², with energy of 3 J in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each isolated lesion that presents with fixed energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. All treatment proposed in group 1 (simulation of PDT + delivery of aciclovir cream) in each patient will be concluded in a single session. Treatment for group 2 (PDT + placebo cream) will also be completed in a single session. All possible adverse effects will be noted and qualified during the treatment protocol and maintenance period (3/3 months) using the questionnaire developed for this protocol.
Study NCT04037475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy herpes labialis
Description: Patients will receive Photodynamic Therapy (PDT), irradiations will be performed with the Laser Duo® red laser diode (MMOptics, São Carlos, SP, Brazil) with a wavelength of 660 nm, with a power of 100 mW, the energy density of 300 J / cm², with energy of 3 J in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each isolated lesion that presents with fixed energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. All treatment proposed in group 1 (simulation of PDT + delivery of aciclovir cream) in each patient will be concluded in a single session. Treatment for group 2 (PDT + placebo cream) will also be completed in a single session. All possible adverse effects will be noted and qualified during the treatment protocol and maintenance period (3/3 months) using the questionnaire developed for this protocol.
Study NCT04267289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: Automated, cognitive behavioral therapy delivered via a website. There are 8 sessions, each taking one to 1.5 hours to complete. Sessions are prerecorded and sequenced. Sessions are based on the principles of cognitive behavioral therapy and include techniques such as cognitive restructuring and behavioral activation. The entire program takes about 8 to 12 weeks to complete.
Study NCT04560270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples to determine ctDNA levels during chemotherapy
Study NCT02171234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02171234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study NCT01676935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: See arm description
Study NCT03433469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO (orally)
Study NCT03433469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02985645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary sinus augmentation with CGF
Description: Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system
Study NCT02985645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic implant valve approach - DIVA system
Description: The DIVA system will be used to apply the CGF to the maxillary sinus.
Study NCT01887080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings.
Study NCT01887080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent
Description: This group had the exercise program after electrolipolysis, thrice a week for eight weeks.~The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).~Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings.
Study NCT01887080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular Risk Factors
Description: It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
Study NCT01887080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular Risk Factors
Description: It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
Study NCT02329548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alizarin Red
Description: An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
Study NCT01417429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: 8mg/a day or placebo
Study NCT01417429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Nicotine
Description: 1.0 mg/70 kg of nicotine against saline
Study NCT03051971 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating Mesh Nebulizer
Description: short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
Study NCT03051971 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer
Description: short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
Study NCT02953938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment
Study NCT02953938 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment
Study NCT02953938 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Grid&Direct short pulse laser photocoagulation
Description: Grid\&Direct short pulse laser photocoagulation is a kind of laser treatment to retina within vascular arcades and used to suppress macular edema
Study NCT05191186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grass pollen extract - Alutard Phleum pratense, ALK
Description: injection in lymph node
Study NCT03592875 — intervention group
Intervention type: BEHAVIORAL
Intervention: Professional nurses
Description: The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
Study NCT03350048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Trans-Dot point-of-care test
Description: Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.~Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response.
Study NCT01226277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0917
Description: Oral repeating dose
Study NCT00617890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: robatumumab
Description: Robatumumab IV every two weeks until disease progression.
Study NCT02799667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressing
Description: Patients are randomized to the standard dressing at the time of fascial closure.
Study NCT02799667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy Dressing
Description: Patients are randomized to the NPWT at the time of fascial closure.
Study NCT00996736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natamycin
Description: 5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
Study NCT03928587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.
Description: One lozenge once daily for 12 months
Study NCT03928587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 months
Study NCT03129945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.
Study NCT00996736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Study NCT01843283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Enhancement Meaningful Activity (DEMA)
Study NCT03129945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.
Study NCT00694473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Navigator
Description: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Study NCT04411511 — intervention group
Intervention type: OTHER
Intervention: Exposure to the Dutch measures due to the Covid-19 pandemic.
Description: Several measures are taken in The Netherlands, due to the Covid-19 virus and pandemic. For example, closure of schools and sportclubs, and advices to stay at home as much as possible. During the pandemic, several measures also will be scaled down.
Study NCT04117620 — intervention group
Intervention type: OTHER
Intervention: Pediatric Vestibular Symptom Questionnaire
Description: Subjects respond to the translated questionnaire twice with 15 days interval
Study NCT01783028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker support
Description: For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
Study NCT00599287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
Study NCT00599287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
Study NCT00599287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
Study NCT01680861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of \<4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
Study NCT01680861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of \<4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
Study NCT01680861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.
Study NCT01680861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
Study NCT03365154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment
Description: Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.
Study NCT03365154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty
Description: Low pressure balloon angioplasty may be used following atherectomy
Study NCT01680861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
Study NCT01680861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
Study NCT05177276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Study NCT05177276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01843283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Support (IS)
Study NCT03577236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenflow Spring System
Description: The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
Study NCT01729702 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample collection
Study NCT00815451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
Study NCT00815451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acticoa polyphenol-rich dark chocolate
Description: 20g to be distributed throughout the day for 4 weeks
Study NCT03602690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir + Darunavir/ritonavir + optimized NRTI
Description: Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
Study NCT05013671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repositioning maneuvers
Description: The calcium crystals floating in the endolymphatic fluid will put back in place by putting the patient in several sitting and lying positions during specific repositioning maneuvers. During these maneuvers the calcium crystals will float from the semicircular canals back into the utriculus, after which the dizziness symptoms should disappear
Study NCT05013671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance
Description: compare the balance of residents with BPPV with residents without BPPV
Study NCT05013671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: balance
Description: compare the balance of residents with BPPV with residents without BPPV
Study NCT03482713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg
Description: Gefapixant 45 mg (film-coated tablet) to be administered orally BID
Study NCT03482713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (film-coated tablet) matching gefapixant to be administered orally BID
Study NCT02768298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.
Study NCT02768298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid.
Study NCT02768298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching enalapril
Description: Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.
Study NCT02768298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching LCZ696
Description: Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.
Study NCT04455659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-cutaneous Electrical Nerve Stimulation
Description: TENS that was applied once daily, three times per week for 8 weeks. Each treatment session was conducted for 20 minutes, two electrodes were positioned over the perineal area between anus and scrotum on the Centrum tendineum, while the other two electrodes were applied under the buttocks medially at the level of the ischial spines (medial to the ischial spines bilaterally) with the patient in comfortable supine hook-lying position with abducted hips. to prevent burn beneath the electrodes, the surface area of the electrode should be equal to or greater than 4 cm2 to minimize the heat production. In addition, to decrease the current density between electrodes, the inter-electrode distance was less than the cross sectional area of the electrode
Study NCT04455659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy exercise
Description: physical therapy program for 30 minutes, and 3 times per week for 8 weeks in the form of strengthening exercise, clam - shell exercise, and stretching exercise focusing on obturator internus muscle, range of motion exercise for the hip and pelvis musculature for 30 minute three times a week for consecutive 8 weeks , each type of exercise was performed for a duration of 6 seconds and repeated 10 times
Study NCT04455659 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy exercise
Description: physical therapy program for 30 minutes, and 3 times per week for 8 weeks in the form of strengthening exercise, clam - shell exercise, and stretching exercise focusing on obturator internus muscle, range of motion exercise for the hip and pelvis musculature for 30 minute three times a week for consecutive 8 weeks , each type of exercise was performed for a duration of 6 seconds and repeated 10 times